JEPQ vs DIVO: returns, risk and drawdowns compared
JPMorgan Nasdaq Equity Premium Income ETF against Amplify CWP Enhanced Dividend Income ETF, over the same 4 years (June 2022 to October 2026) with dividends reinvested.
Data updated October 2026
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
10,000 became
19,850
- A year on average
- +16.8%
- Annual volatility
- 13.7%
- Deepest fall
- −13.5%
- Worst month
- −8.8%
DIVO
Amplify CWP Enhanced Dividend Income ETF
10,000 became
16,647
- A year on average
- +12.2%
- Annual volatility
- 11.8%
- Deepest fall
- −9.6%
- Worst month
- −6.9%
JEPQ came out ahead by 4.6 percentage points a year from June 2022 to October 2026. JEPQ swung more (13.7% against 11.8% a year). The correlation of monthly returns was 0.63: they moved together only in part.
Growth of 10,000: JEPQ vs DIVO
Who was ahead, and when
The gap between the two over the previous three years, at each month-end. Above zero JEPQ had returned more, below zero DIVO. JEPQ was ahead in 100% of the 18 three-year periods.
Annualised 3-year return of JEPQ minus that of DIVO, in percentage points a year.
Falls from the previous high
Month-end values. Deepest fall: JEPQ −13.5%, DIVO −9.6%.
All the figures
| JEPQ | DIVO | |
|---|---|---|
| Annual return (CAGR) | +16.8% | +12.2% |
| Total return | +99% | +66% |
| Annual volatility | 13.7% | 11.8% |
| Deepest fall (month-end) | −13.5% | −9.6% |
| Worst month | −8.8% | −6.9% |
| Best month | +8.2% | +11.3% |
| Positive months | 70% | 64% |
| Best year | 2023: +36.3% | 2025: +17.4% |
| Worst year | 2025: +15.2% | 2023: +7.0% |
| 1-year return | +16.3% | +15.3% |
| 5 years, a year | — | +11.0% |
| 10 years, a year | — | — |
| Trading currency | USD | USD |
First nine rows: the same 53 months for both funds. Trailing returns: to each fund’s last close.
Year by year
Full calendar years both funds were trading. The higher of the two each year is in bold.
Holding both: half JEPQ, half DIVO
| JEPQ alone | DIVO alone | 50/50 | |
|---|---|---|---|
| A year on average | +16.8% | +12.2% | +14.7% |
| Annual volatility | 13.7% | 11.8% | 11.5% |
| Deepest fall (month-end) | −13.5% | −9.6% | −10.9% |
| Worst month | −8.8% | −6.9% | −7.9% |
Because the two did not always move together, the mix swung less than the average of the two (11.5% against 12.7%). Rebalanced to 50/50 every month, before costs.
Questions
Which has returned more, JEPQ or DIVO?
From June 2022 to October 2026, JEPQ returned +16.8% a year and DIVO +12.2% a year, with dividends reinvested. Over rolling 3-year periods JEPQ did better in 100% of cases. Past returns do not predict future returns.
Which is riskier, JEPQ or DIVO?
Over the same months annual volatility was 13.7% for JEPQ and 11.8% for DIVO; the deepest fall from a month-end high was 13.5% and 9.6%, and the worst single month −8.8% and −6.9%.
How correlated are JEPQ and DIVO?
The correlation of their monthly returns was 0.63: they moved together only in part. Combining them has historically given some diversification.
What about holding both JEPQ and DIVO?
Half in each, rebalanced every month, returned +14.7% a year over the same period, with 11.5% annual volatility and a deepest month-end fall of 10.9%.
More comparisons
- JEPQ — JPMorgan Nasdaq Equity Premium Income ETFReturns, drawdowns and risk
- DIVO — Amplify CWP Enhanced Dividend Income ETFReturns, drawdowns and risk
- JEPI vs JEPQ
- JEPQ vs QYLD
- JEPI vs DIVO
- QYLD vs DIVO
- Backtest a portfolio with rebalancing and costsRebalancing, costs and attribution
- Portfolio analytics software comparedFeatures and prices side by side
How the figures are calculated
Total return in the fund’s trading currency, from end-of-day prices with dividends reinvested on the ex-date. The fund’s own ongoing charges are already reflected in its price; trading costs, taxes and currency conversion are not included. Past returns do not predict future returns.
The comparison uses only the months in which both funds have prices, so the figures cover the same period even when one fund is older.
Source: MarketStack end-of-day prices, total return with dividends reinvested. Figures are historical and descriptive; they are not forecasts and not investment advice. MEDGE Capital does not recommend buying or selling any instrument. Risk disclaimer.